HSPG2 and hepatocellular carcinoma: Building upon this, Li et al. expanded drug responses from PLC organoids by using a panel of 129 cancer drugs on HCC and CCA organoid lines, finding that there is a substantial intertumour as well as intratumour heterogeneity present [77], highlighting the importance of using organoids as part of the pre-clinical drug discovery pipeline.